The impact of the COVID-19 pandemic on the Management of Locally Advanced Primary/Recurrent Rectal Cancer. British Journal of Surgery. 10, 01/08/2020.
Predicting outcomes of pelvic exenteration using machine learning. Colorectal Disease. 01/07/2020.
Management strategies for patients with advanced rectal cancer and liver metastases using modified Delphi methodology: results from the PelvEx Collaborative. Colorectal Disease. 11, 01/02/2020.
The impact of the COVID-19 pandemic on the Management of Locally Advanced Primary/Recurrent Rectal Cancer. Ann Surg.270 – 5, pp. 899 – 905. 01/11/2019.
Palliative pelvic exenteration: A systematic review of patient-centered outcomes. Eur J Surg Oncol. 45 – 10, pp. 1787 – 1795. 01/10/2019.
Changing outcomes following pelvic exenteration for locally advanced and recurrent rectal cancer. BJS Open. 3, pp. 516 – 520. BJS, 01/03/2019.
Wenceslao Vásquez Jiménez. Late bleeding due to FXIII deficiency following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Rev Argent Anestesiol.76 – 2, pp. 93 – 98. 05/02/2019.
Surgical and Survival Outcomes Following Pelvic Exenteration for Locally Advanced Primary Rectal Cancer: Results From an International Collaboration. PelvEx Collaborative.Ann Surg.269 – 2, pp. 315 – 321. Annals of Surgery, 01/01/2019.
PELVEX; Wenceslao Vasquez Jimenez. Minimally invasive surgery techniques in pelvic exenteration: a systematic and meta-analysis review.Surg Endosc.32 – 12, pp. 4707 – 4715. Surgical endoscopic, 01/12/2018.
Factors affecting outcomes following pelvic exenteration for locally recurrent rectal cancer. PelvEx Collaborative.Br J Surg.105 – 6, pp. 650 – 657. British Journal of Surgery, 01/05/2018.